EMBC241220C22500
- 0.40
- +0.20+100.00%
Embecta Newsroom
Embecta Analyst Ratings
BTIG Upgrades Embecta to Buy, Announces $26 Price Target
Morgan Stanley Maintains Embecta(EMBC.US) With Sell Rating, Maintains Target Price $13
BTIG Upgrades Embecta(EMBC.US) to Buy Rating, Announces Target Price $26
Embecta Corporation: Discontinued Patch Pump Program and Financial Shortfalls Prompt Sell Rating
Embecta Corporation's Strategic Shifts and Revenue Outlook Prompt 'Sell' Rating
Morgan Stanley Maintains Embecta(EMBC.US) With Sell Rating, Maintains Target Price $13
BTIG Maintains Embecta(EMBC.US) With Hold Rating
BTIG Reaffirms Their Hold Rating on Embecta Corporation (EMBC)
Morgan Stanley Maintains Embecta(EMBC.US) With Sell Rating, Raises Target Price to $13
Recommendation to Sell: Anticipated Costs and Competition Challenge Embecta's New Pump Program
Analysts Conflicted on These Healthcare Names: Healthequity (HQY) and Embecta Corporation (EMBC)
BTIG Remains a Hold on Embecta Corporation (EMBC)
Embecta Analyst Ratings
Morgan Stanley Lowers Price Target on Embecta to $12 From $13, Maintains Underweight Rating
Embecta Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Embecta Corporation (EMBC) and Abbott Labs (ABT)
Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC), Mettler-Toledo (MTD) and Humacyte (HUMA)
Morgan Stanley Adjusts Price Target on to $16 From $15, Maintains Underweight Rating